Clinical Trials Market Size, Share, By Services (Project Management, and Site Management, Medical Writing & Medical Monitoring, Laboratory Services, Clinical Data Management, and Others), Phase Type (Phase I, Phase II, Phase III, and Phase IV), Study Design (Interventional, Treatment Studies, Observational Studies, and Expanded Access), Indication (Autoimmune, Pain Management, Oncology, CNS Condition, Cardiovascular, Diabetes, Obesity, and Others), End-User (Hospitals, Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Research Laboratories) and Region - Trends, Analysis, and Forecast till 2035

The key players operating in the clinical trials include IQVIA, Labcorp, Thermo Fisher Scientific Inc. and others. These key players are focusing on improving on research and development, innovative strategies, new drug development practices, strategic partnerships and acquisitions to enhance clinical trial procedures, resulting to growth of target market share.

List of Key Players in the Market:

• IQVIA
• Labcorp
• Thermo Fisher Scientific Inc.
• Eli Lily and Company
• Syneos Health
• Medpace
• Charles River Laboratories
• Advanced Clinical
• Crown Bioscience
• Parexel International (MA) Corporation
• Pfizer, Inc.
• Frontage Labs
• CTI Clinical Trial & Consulting
• Caidya
• Reliance Life Sciences

Recent News:

• In February 2025, CuraSen Therapeutics, Inc., announced first subject treated with CuraAX, an alpha-1A adrenoceptor agonist, in Phase I clinical trials. CuraAX was aimed to treat patient with neurogenic orthostatic hypotension (nOH) by offering potential to provide stable, and durable efficacy, improve safety and dose convenience in patients. The Phase 1 trial, was objective to assess the safety, tolerability and pharmacokinetics of CuraAX, to evaluate multiple dose levels of CuraAX in approximately 56 healthy volunteers.
• In February 2025, Vaxxas received USD 28.5 million funding from the U.S. Department of Health and Human Services (DHHS) for the trials of Phase I avian influenza A (H7N9) vaccine. H7N9 is delivered through microneedle patch applied to the skin, and the company had successfully enrolled 258 patients with company’s primary influenza vaccine.
• In February 2025, Akeso, Inc., announced enrolled of the first patient in its Phase III clinical trial for the treatment of triple-negative breast cancer (TNBC). Phase III trials confirming the efficacy and safety of a new treatment, as a first-line treatment in patients with unrespectable locally advanced or metastatic TNBC.
• In January 2025, World Health Organization (WHO) consultation established country-led platform for clinical trials of tuberculosis (TB).  This platform aimed to streamline the process of conducting TB treatment trials, making it more efficient and collaborative. By streamlining the clinical trial process and focused on a collaborative platform, this initiative aimed to speed up the development of new TB treatments. This could lead to the introduction of more effective therapies, for drug-resistant TB, which remains a global health risk.
• In October 2024, The National Institutes of Health launched a precision medicine clinical trial to test treatment combinations by targeting specific changes in a cancer cells. It was aimed to target patient with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The trials was funded by NIH’s National Cancer Institute (NCI), aimed to accelerate the discovery of more tailored treatment for aggressive cancers of blood and bone marrow.